New Clinical Trial Tests Immune-Protected Insulin Cell Implant for Type 1 Diabetes

Type 1 diabetes destroys the insulin-producing cells in the pancreas, forcing people to manage blood sugar through insulin injections or pumps. Transplanting healthy islet cells from donors could theoretically address the root cause—replacing the lost cells rather than treating symptoms. But there's a major obstacle: the immune system attacks the transplanted cells just as it attacked the original ones.

Current islet transplant recipients must take immunosuppressive medications for life to prevent rejection. These drugs carry serious risks, including increased infections and cancer risk. Encellin is pursuing a different strategy: encapsulating donor islet cells in a special membrane that shields them from immune attack while still allowing insulin to pass through and reach the bloodstream.

Encellin completed a first-in-human Phase 1 study (NCT06408311) that implanted their ENC-201 device in patients with Type 1 diabetes. When researchers later retrieved the implants, they found encouraging signs: the device integrated into surrounding tissue without causing fibrosis (excessive scarring), new blood vessels had grown around it, and the transplanted human islet cells remained viable and functional.

These results validated the basic concept—that the encapsulated islets could survive in the body and maintain their ability to produce insulin. But a single early study cannot yet prove the therapy will work safely or effectively in larger populations or over the long term.

With support from Breakthrough T1D's Industry Discovery and Development Partnership program, Encellin is now launching a new clinical trial (NCT07680673) in Canada. This trial will test ENCRT-103-hPI, a next-generation implant configuration designed to improve on the original device.

The study will focus on safety, tolerability, and how well the implant works. Specifically, researchers will evaluate how the implant integrates with body tissue, whether the protective membrane successfully blocks immune cells from reaching the transplanted islets, whether the donor cells survive over time, and what local tissue responses occur around the device.

If an immune-protected islet cell implant proves safe and effective, it could eventually offer Type 1 diabetes patients a way to restore natural insulin production without the risks of long-term immunosuppressive therapy. Rather than managing the disease through daily insulin dosing, some patients might be able to rely on their transplanted cells to regulate blood sugar.

It's important to note that this remains an early-stage therapy in human testing. Many promising approaches in clinical trials do not ultimately reach patients. The coming trial will answer foundational questions about safety and feasibility, not yet about whether the therapy improves blood sugar control or quality of life.

Origin: biospace.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.